|
Synonyms: AOC 1001 | AOC-1001 | del-desiran
Compound class:
Nucleic acid
Comment: Delpacibart etedesiran (AOC 1001) is structurally a monoclonal antibody (mAb)-oligonucleotide conjugate (AOC) in which the mAb binds the transferrin receptor (TFRC;) for targeted delivery of a duplex small interfering RNA (siRNA) payload that degrades the mRNA that encodes DM1 protein kinase (DMPK) [1].
This entry provides information on the siRNA as the component that mediates the agent's intended pharmacodynamic effect. Further details about the parental anti-TFRC mAb are provided in the delpacibart entry. To improve pharmacokinetics and RNA binding the nucleotides in etedesiran are chemically modified (2'-O-methyl/2'-MOE monomers), with a mixed phosphorothioate/phosphate backbone. The mAb is attached to the siRNAs via malemide linkers at Cys-R positions on the passenger strands. Delpacibart etedesiran is proposed to reduce the global splicing defects that arise from toxic gain-of-function DMPK transcript accummulation in myocytes in myotonic dystrophy type 1. |
Classification ![]() |
|
| Compound class | Nucleic acid |
| Compound subclass | siRNA |
| Target | DM1 protein kinase (DMPK) mRNA |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 12400 | delpacibart etedesiran |
Synonyms ![]() |
| AOC 1001 | AOC-1001 | del-desiran |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1375 |
| Other databases | |
| CAS Registry No. | 2653183-68-5 (source: WHO INN record) |
| Search PubMed clinical trials | delpacibart etedesiran |
| Search PubMed titles | delpacibart etedesiran |
| Search PubMed titles/abstracts | delpacibart etedesiran |